Janus kinase inhibitors: An innovative treatment for alopecia areata

Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib

(2018) Ji Su Lee et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

(2018) A. Jabbari et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

(2018) Nawaf Almutairi et al.   DERMATOLOGY

Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series

(2017) Hyun-Sun Park et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients

(2017) Lucy Y. Liu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib for the treatment of alopecia areata and variants in adolescents

(2017) Brittany G. Craiglow et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Treatment of Alopecia Areata With Tofacitinib

(2017) Omer Ibrahim et al.   JAMA Dermatology

Genome-wide association study in alopecia areata implicates both innate and adaptive immunity

(2010) Lynn Petukhova et al.   NATURE

Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack

(2007) Taisuke Ito et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY